ArticleJAMA network open2019

Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.

Louis Everest et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.